Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  IQVIA Holdings Inc.    IQV

IQVIA HOLDINGS INC.

(IQV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

IQVIA : Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness

07/29/2020 | 08:08am EST

Orchestrate intelligent and agile strategies for personalized customer engagement

IQVIA™ (NYSE: IQV) today introduced OCE Optimizer, an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s Orchestrated Customer Engagement solution by intelligently allocating commercial resources and interaction channels for more effective connections.

“The life sciences industry is becoming more dynamic and specialized,” said Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA. “The current environment is driving organizations to transform sales and marketing toward an increasingly digital model that orchestrates timely HCP touchpoints across multiple channels. OCE Optimizer provides customers with agile tools to adapt engagement strategies in response to market factors and prior HCP interactions.”

Traditional long-range planning based on annual territory alignments is no longer sufficient. Life sciences companies are coordinating multiple customer-facing teams and interacting with a diverse set of decision-makers in healthcare networks. OCE Optimizer offers a new approach that creates and continuously updates rules-based workflows to create custom engagement plans across personal and digital channels.

OCE Optimizer leverages IQVIA’s Ada machine learning algorithms to draw intelligent insights from varied information sources, including healthcare organization affiliations, call reports and access changes. With a detailed and current profile of every HCP, commercial teams then use OCE Optimizer to make on-demand course corrections to field alignments, segments and targets, and omnichannel engagement plans using visual tools and what-if scenarios for complex territory alignments.

For more information on OCE Optimizer, visit https://www.iqvia.com/oceoptimizer.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.


© Business Wire 2020
All news about IQVIA HOLDINGS INC.
11/19IQVIA : Q3 2020 Earnings Call - Presentation
PU
11/02IQVIA : 's Orchestrated Customer Engagement Platform Selected by Zentiva to Acce..
BU
10/22IQVIA : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
10/20IQVIA : 3Q Earnings Snapshot
AQ
10/20IQVIA HOLDINGS INC. : Results of Operations and Financial Condition, Financial S..
AQ
10/20IQVIA : Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and P..
BU
10/15IQVIA HOLDINGS INC. : quaterly earnings release
10/12IQVIA : Joins FDA to Advance COVID-19 Understanding at Community Level through C..
BU
10/07IQVIA : to Announce Third-Quarter Results on October 20, 2020
BU
10/06IQVIA INSTITUTE FOR HUMAN DATA SCIEN : Biosimilars Reach Inflection Point &ndash..
BU
More news
Financials (USD)
Sales 2020 11 206 M - -
Net income 2020 332 M - -
Net Debt 2020 10 414 M - -
P/E ratio 2020 98,8x
Yield 2020 -
Capitalization 32 365 M 32 365 M -
EV / Sales 2020 3,82x
EV / Sales 2021 3,41x
Nbr of Employees 68 000
Free-Float 74,5%
Chart IQVIA HOLDINGS INC.
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 196,26 $
Last Close Price 168,81 $
Spread / Highest target 34,5%
Spread / Average Target 16,3%
Spread / Lowest Target -7,00%
EPS Revisions
Managers
NameTitle
Ari Bousbib Chairman, President & Chief Executive Officer
James Grant Berkshire Senior Vice President-Business Operations
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
John M. Leonard Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IQVIA HOLDINGS INC.9.26%32 568
LONZA GROUP AG55.15%44 901
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 811
SEAGEN INC.44.80%29 832
IMMUNOMEDICS, INC.315.22%20 324